Cas no 630-93-3 (Phenytoin sodium)

Phenytoin sodium is an anticonvulsant drug primarily used to control and prevent seizures in epilepsy. Its chemical structure, derived from hydantoin, allows it to stabilize neuronal membranes by inhibiting voltage-gated sodium channels, thereby reducing abnormal electrical activity in the brain. The sodium salt formulation enhances solubility, improving bioavailability for oral and intravenous administration. Phenytoin sodium is particularly effective in treating tonic-clonic and partial seizures, as well as preventing seizures following neurosurgery or traumatic brain injury. Its long half-life permits less frequent dosing, though therapeutic drug monitoring is recommended due to its narrow therapeutic index and potential for drug interactions. Proper storage in airtight containers is essential to maintain stability.

Phenytoin sodium structure

Product Name:Phenytoin sodium

CAS No:630-93-3

MF:C₁₅H₁₁N₂NaO₂

MW:274.2498

MDL:MFCD00069674

CID:39287

PubChem ID:23679632

Update Time:2025-09-28

Phenytoin sodium Chemical and Physical Properties

Names and Identifiers

- 5,5-diphenyl-2,4-imidazolidinedione monosodium salt
- 5,5-DIPHENYL-2,4-IMIDAZOLIDINEDIONE SODIUM SALT
- 5,5-DIPHENYLHYDANTOIN SODIUM
- 5,5-DIPHENYLHYDANTOIN SODIUM SALT
- DILANTIN
- DIPHENYLHYDANTOIN SODIUM SALT
- PHENYLTOIN SODIUM
- PHENYTOIN SODIUM
- PHENYTOIN SODIUM SALT
- sodium 5,5-diphenyl-2,4-imidazolidinedione
- SODIUM 5,5-DIPHENYLHYDANTOIN
- SODIUM DIPHENYLHYDANTOIN
- 4-imidazolidinedione,5,5-diphenyl-monosodiumsalt
- 5,5-diphenyl-hydantoimonosodiumsalt
- 5,5-diphenyl-hydantoisodiumsalt
- alepsin
- aleviatinsodium
- auranile
- denylsodium
- 5,5-DIPHENYLHYDANTOIN
- 5,5-diphenyl-hydantoine
- 5,5-diphenylimidazolidine-2,4-dione sodium salt
- dihydan
- dilantin sodium
- di-len
- ditoin
- enkefal
- epelin
- epinat
- eptoin
- solantyl
- tacosal
- Diphenylhydantoin sodium
- Diphantoine
- Fenidantoin
- Novodiphenyl
- Phenilep
- Hidantin
- Epsolin
- Epdantoin
- Ditomed
- Fenytoin
- Fenigramon
- Derizene
- Fenitron
- Eptolin
- Epileptin
- Decatona
- Cumatil
- Aladdin
- Episar
- Muldis
- Hidantal sodium
- Fenitoin sodium
- Lepitoin sodium
- Denyl sodium
- Aleviatin sodium
- Sodium phenytoin
- Diphenine sodium
- Fenitoina Sodica
- Epilantin-E
- Soluble phenytoin
- Metinal Idantoina
- Dilantin Infata
- Diphentoin
- Hydantoin, 5,5-diphenyl-, sodium salt
- Phenytoin sodium,prompt
- HMS1920H10
- Tox21_302338
- PHENYTOIN SODIUM [MART.]
- AKOS025310163
- Diphenylan sodium
- PHENYTOIN SODIUM [VANDF]
- NCGC00164434-01
- Q-201564
- Antisacer
- PHENYTOIN SODIUM, PROMPT
- PHENYTOIN SODIUM [USP-RS]
- SPECTRUM1500485
- 5,5-Diphenyl-2,4-imidazolidinedione, monosodium salt
- PHENYTOIN SODIUM (EP MONOGRAPH)
- SR-05000001698
- DTXSID2023775
- SMR000058987
- Phenytoin sodium (USP:JAN)
- fenitoinsodium
- PHENYTEK
- HMS2091P14
- Prompt Phenytoin Sodium
- Phenytoin sodium,extended
- EINECS 211-148-2
- Dilantin Infatabs
- H12023
- AKOS015951389
- Dilantin Suspension
- Sodium 5,5-diphenylhydantoinate
- Sodium 5,5-diphenyl hydantoinate
- SDPH
- 4182431BJH
- 630-93-3
- Sodium diphenyl hydantoinate
- PHENYTOINUM NATRICUM [WHO-IP LATIN]
- MLS000028562
- NCGC00255285-01
- SCHEMBL3051683
- Extended Phenytoin Sodium
- NSC-757274
- UNII-4182431BJH
- Dilantin Injection
- PHENYTOIN SODIUM (USP MONOGRAPH)
- D1331
- PHENYTOINER
- Hydantoin, 5,5-diphenyl-, monosodium salt
- HMS2233K24
- Phenytoin sodium, Pharmaceutical Secondary Standard; Certified Reference Material
- SMR000146393
- Citrullamon
- 5,5-Diphenylhydatoin sodium salt
- PHENYTOIN SODIUM FOR INJECTION [JAN]
- PHENYTOIN SODIUM [WHO-IP]
- 5,5-Diphenylhydantoin sodium salt, >=99%
- sodium;5,5-diphenylimidazolidin-3-ide-2,4-dione
- Diphenylhydantoin, sodium salt
- PHENYTOIN SODIUM,EXTENDED [VANDF]
- NSC 757274
- HMS501J09
- NC00642
- PHENYTOIN SODIUM EXTENDED [VANDF]
- PHENYTOIN SODIUM [USP MONOGRAPH]
- Epanutin
- PHENYTOIN SODIUM, EXTENDED
- DIPHENYLHYDANTOIN SODIUM [GREEN BOOK]
- Diphenylhydantoinate, Sodium
- DTXCID803775
- PHENYTOIN SODIUM (MART.)
- PHENYTOIN SODIUM [WHO-DD]
- CCG-39219
- Opera_ID_1233
- AKOS003273947
- OM-Hydantoine sodium
- 2,4-Imidazolidinedione, 5,5-diphenyl-, monosodium salt
- Diphenylhydantoin (Phenytoin), sodium salt
- HMS3373O11
- CAS-630-93-3
- PHENYTOIN SODIUM (USP-RS)
- 2,4-Imidazolidinedione, 5,5-diphenyl-, sodium salt (1:1)
- sodium 2,5-dioxo-4,4-diphenylimidazolidin-1-ide
- NCGC00094758-01
- Phenytoin sodium [USP:JAN]
- Phenytoin sodium, European Pharmacopoeia (EP) Reference Standard
- HMS3259H11
- SR-05000001698-1
- Solantoin
- MFCD00069674
- Phenytoin sodium, United States Pharmacopeia (USP) Reference Standard
- Q27258415
- Phenytoin sodium extended
- AS-13308
- PHENYTOIN SODIUM,PROMPT [VANDF]
- PHENYTOIN SODIUM (EP IMPURITY)
- PHENYTOIN SODIUM SALT [MI]
- PHENYTOIN SODIUM [ORANGE BOOK]
- Phenytoin, sodium salt
- PHENYTOIN SODIUM [EP MONOGRAPH]
- MLS000554076
- PHENYTOIN SODIUM [EP IMPURITY]
- NCGC00094758-02
- Phenytoin sodium
- MDL： MFCD00069674
- Inchi： 1S/C15H12N2O2.Na/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12;/h1-10H,(H2,16,17,18,19);/q;+1/p-1
- InChI Key： FJPYVLNWWICYDW-UHFFFAOYSA-M
- SMILES： [Na+].O=C1C(C2C([H])=C([H])C([H])=C([H])C=2[H])(C2C([H])=C([H])C([H])=C([H])C=2[H])N([H])C([N-]1)=O

Computed Properties

Exact Mass: 274.07200
Monoisotopic Mass: 274.072
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 1
Hydrogen Bond Acceptor Count: 3
Heavy Atom Count: 20
Rotatable Bond Count: 2
Complexity: 356
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Topological Polar Surface Area: 47.2
Surface Charge: 0
Topological Polar Surface Area: 47.2

Experimental Properties

Color/Form: White powder
Melting Point: 295-298°C
Boiling Point: 428.2oC at 760 mmHg
Flash Point: 212.8oC
Solubility: aqueous base: soluble
PSA: 49.41000
LogP: 2.21300
Merck: 7322
Solubility: Soluble in water, soluble in ethanol, almost insoluble in ether and chloroform
Sensitiveness: Sensitive to humidity
Vapor Pressure: No data available

Phenytoin sodium Security Information

Symbol:
Prompt：dangerous
Signal Word：Warning
Hazard Statement： H302,H317,H361
Warning Statement： P280
Hazardous Material transportation number：UN 2811 6.1/PG 3
WGK Germany：3
Hazard Category Code： 63-22-43-62
Safety Instruction： S22-S36/37/39-S45
RTECS：MU1400000
Hazardous Material Identification：
Toxicity：LD50 orally in mice: 490 mg/kg (Fink, Swinyard)
Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Packing Group：III
Risk Phrases：R22; R43; R62; R63
Hazard Level：6.1(b)
HazardClass：6.1
PackingGroup：III

Phenytoin sodium Customs Data

HS CODE：29332100
Customs Data：

China Customs Code:
2933990090

Overview:

2933990090. Other heterocyclic compounds containing only nitrogen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

Declaration elements:

Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date

Summary:

2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Phenytoin sodium Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI	BP7472-100g	Phenytoin sodium	630-93-3	≥98%	100g	￥420元	2023-09-15
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI	BP7472-25g	Phenytoin sodium	630-93-3	≥98%	25g	￥150元	2023-09-15
DC Chemicals	DC9024-1 g	Phenytoin sodium	630-93-3	>98%	1g	$300.0	2022-02-28
SHANG HAI SHAO YUAN SHI JI Co., Ltd.	SY005387-25g	5,5-Diphenylhydantoin Sodium Salt	630-93-3	≥98%	25g	￥29.40	2024-07-09
SHANG HAI SHAO YUAN SHI JI Co., Ltd.	SY005387-100g	5,5-Diphenylhydantoin Sodium Salt	630-93-3	≥98%	100g	￥117.60	2024-07-09
SHANG HAI SHAO YUAN SHI JI Co., Ltd.	SY005387-500g	5,5-Diphenylhydantoin Sodium Salt	630-93-3	≥98%	500g	￥588.00	2024-07-09
TRC	D491655-50mg	5,5-Diphenyl Hydantoin Sodium	630-93-3		50mg	$ 57.00	2023-09-07
TRC	D491655-1g	5,5-Diphenyl Hydantoin Sodium	630-93-3		1g	$ 63.00	2023-09-07
TRC	D491655-10g	5,5-Diphenyl Hydantoin Sodium	630-93-3		10g	$ 75.00	2023-09-07
TRC	D491655-25g	5,5-Diphenyl Hydantoin Sodium	630-93-3		25g	$97.00	2023-05-18

Phenytoin sodium Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:630-93-3)Phenytoin Sodium

Order Number:LE11919;LE1765492

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 12:06

Price ($):discuss personally

Email:[email protected]

Zhengzhou Baoyu Pharmaceutical Co., Ltd.

Gold Member

Audited Supplier

(CAS:630-93-3)Phenytoin sodium

Order Number:LE244

Stock Status:in Stock

Quantity:5KG/1KG/25KG/100KG

Purity:99% HPLC

Pricing Information Last Updated:Thursday, 14 August 2025 14:44

Price ($):negotiated

Email:[email protected]

Phenytoin sodium Related Literature

1. Fabrication and characterization of biocompatible pH responsive halloysite nanotubes grafted with sodium alginate for sustained release of phenytoin sodium

Leila Zeraatpishe,Alireza Mohebali,Majid Abdouss New J. Chem. 2019 43 10523
2. Construction and application of phenytoin anion-selective electrode based on bulk acoustic wave (BAW) sensing technique

Yumei Long,Yingjiu Liu,Lihong Lei,Lihua Nie,Shouzhuo Yao Analyst 2001 126 1090
3. Recent advances in the design of inorganic and nano-clay particles for the treatment of brain disorders

Francesca Persano,Svetlana Batasheva,G?lnur Fakhrullina,Giuseppe Gigli,Stefano Leporatti,Rawil Fakhrullin J. Mater. Chem. B 2021 9 2756
4. A review of past promises, present realities and a vibrant future for wound dressing from naturally occurring to sustainable materials

Supriya H.,Sandeep Tripathi,Suryasarathi Bose RSC Sustain. 2023 1 763
5. Derivative spectrophotometric analysis of two-component mixtures using a compensation technique

Abdel-Aziz M. Wahbi,Fawzy A. El-Yazbi,Magda H. Barary,Suzy M. Sabri Analyst 1992 117 785

Related Categories

Additional information on Phenytoin sodium

Phenytoin sodium (CAS No. 630-93-3): A Comprehensive Overview

Phenytoin sodium, a compound with the chemical formula C?H?NO?·Na, is a well-established anticonvulsant medication primarily used to treat various types of epilepsy. With a CAS number of 630-93-3, this compound has been a cornerstone in neurology for decades, and its mechanism of action, pharmacokinetics, and therapeutic applications continue to be subjects of extensive research. This article provides an in-depth exploration of phenytoin sodium, integrating the latest findings from clinical studies and academic research to offer a comprehensive understanding of its role in modern medicine.

The history of phenytoin sodium dates back to the mid-20th century when it was first synthesized and introduced as an effective treatment for seizure disorders. Over the years, its efficacy and safety profile have been well-documented, making it one of the most widely prescribed anticonvulsants globally. The compound's unique chemical structure, featuring a benzhydryl group and a piperidine ring, contributes to its ability to modulate neuronal activity by inhibiting voltage-gated sodium channels. This mechanism is pivotal in reducing the frequency and severity of seizures, thereby improving the quality of life for patients with epilepsy.

Recent advancements in pharmacogenomics have shed new light on the variability in phenytoin sodium response among patients. Studies have identified specific genetic markers that influence drug metabolism and efficacy, leading to more personalized treatment approaches. For instance, variations in the CYP2C9 gene have been shown to affect the metabolism of phenytoin, potentially explaining differences in therapeutic outcomes. This insight has paved the way for genetic testing to guide dosing regimens, optimizing patient care and minimizing adverse effects.

The pharmacokinetic profile of phenytoin sodium is characterized by its low bioavailability and significant interindividual variability. After oral administration, the drug undergoes extensive first-pass metabolism, which can lead to lower systemic exposure compared to intravenous formulations. Additionally, phenytoin's interaction with other medications is well-documented, particularly with drugs that induce or inhibit its metabolism. For example, concomitant use of carbamazepine can increase phenytoin clearance, while rifampicin may enhance its toxicity due to enzyme induction. These interactions underscore the importance of careful monitoring when phenytoin is prescribed as part of combination therapy.

Despite its long history of use, phenytoin sodium remains a subject of ongoing research due to its complex pharmacological properties. Recent studies have explored its potential role beyond traditional anticonvulsant therapy. For instance, preclinical research suggests that phenytoin may exhibit neuroprotective effects against excitotoxicity and oxidative stress, making it a candidate for treating neurodegenerative diseases such as Alzheimer's and Parkinson's disease. While clinical trials are still in progress, these findings highlight the multifaceted therapeutic potential of this compound.

The clinical applications of phenytoin sodium extend beyond epilepsy management. It has been used effectively in treating status epilepticus, a life-threatening condition where seizures persist for an extended period. The rapid onset of action makes it a preferred choice in emergency settings where immediate control of seizures is critical. Furthermore, phenytoin's antiarrhythmic properties have been explored in managing certain types of cardiac arrhythmias, particularly those involving increased intracranial pressure.

Economic considerations also play a significant role in the widespread use of phenytoin sodium. As one of the oldest anticonvulsants on the market, it is available as a generic medication in many countries, making it an affordable option for patients worldwide. However, despite its cost-effectiveness, issues such as poor patient adherence due to side effects continue to pose challenges. Recent initiatives have focused on improving formulations to enhance tolerability while maintaining efficacy.

The future direction of research on phenytoin sodium is likely to focus on optimizing its therapeutic index and exploring novel applications. Advances in drug delivery systems may lead to more targeted therapies with reduced systemic side effects. Additionally, investigating synergistic combinations with other antiepileptic drugs could provide better control over refractory epilepsy cases. As our understanding of neuronal function evolves, phenytoin sodium may continue to reveal unexpected therapeutic benefits beyond its established uses.

630-93-3 (Phenytoin sodium) Related Products

Recommended suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

(CAS:630-93-3)Phenytoin Sodium

Purity:99%/99%

Quantity:25KG,200KG,1000KG/25KG,200KG,1000KG

Price ($):Inquiry/Inquiry